Product Description
FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types. FPI-1434 utilizes Fusion's Fast-Clear linker to connect a human monoclonal antibody that targets IGF-1R with actinium-225, a powerful alpha-emitting isotope with desirable half-life and decay chain properties. (Sourced from: https://ir.fusionpharma.com/2022-06-09-Fusion-Pharmaceuticals-Provides-Updates-on-FPI-1434-and-FPI-1966-Clinical-Programs)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Adrenocortical Carcinoma|Cervical Cancer|Endometrial Cancer|Head and Neck Cancer|Ovarian Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FPX-01-01 | P2 |
Recruiting |
Uveal Melanoma|Triple Negative Breast Cancer|Cervical Cancer|Ovarian Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Adrenocortical Carcinoma|Endometrial Cancer |
2025-06-01 |